Bullish indicating open at $55-$60, IPO prices at $37
Kura Oncology, Inc. (NASDAQ:KURA) announced that it has entered into a co-promotion and medical affairs agreement with Kyowa Kirin, Inc. to jointly promote Kura’s investigational drug ziftomenib for the treatment of acute myeloid leukemia and other blood cancers in the United States. The agreement was signed on Friday, according to a statement based on a Securities and Exchange Commission filing.
Under the terms of the co-promotion agreement, Kyowa Kirin US will have the right and responsibility to co-promote ziftomenib for up to a specified percentage of promotional activities in the US. Kyowa Kirin US is required to meet minimum detailing requirements using qualified sales representatives. Both companies will share equally in all costs and expenses related to these activities, in accordance with a prior collaboration and license agreement dated November 20, 2024. This strategic partnership comes as analysts anticipate sales growth for Kura in the current year, with five analysts recently revising their earnings estimates upward, according to InvestingPro analysis. For comprehensive insights into Kura’s financial health and growth potential, investors can access the detailed Pro Research Report, available exclusively to InvestingPro subscribers.
Kura Oncology will lead all medical affairs activities for ziftomenib in the US, while coordinating and receiving input from Kyowa Kirin US. The companies will also jointly develop the health economics and outcomes research strategy for the drug, sharing costs equally.
The agreement will remain in effect until both parties agree to end commercialization of ziftomenib in the US or until the expiration of the US term under the collaboration agreement. The term is defined as the latest of the expiration of all valid patent claims licensed to Kyowa Kirin in the US, the expiration of the last-to-expire regulatory exclusivity in the US, or ten years after the first commercial sale in the US. The co-promotion agreement will automatically terminate if the collaboration agreement ends, and either party may terminate the agreement for an uncured material breach by the other party. Despite trading near its 52-week low, analyst consensus remains optimistic with a price target range of $8 to $40, suggesting significant potential upside from current levels.
Kura Oncology stated that it intends to file the full text of the agreement, with confidential terms redacted, as an exhibit to its quarterly report for the period ended June 30, 2025. This information is based on a press release statement and a recent SEC filing.
In other recent news, Kura Oncology has been the focus of several analyst updates and clinical trial results. Cantor Fitzgerald maintained its overweight rating on Kura Oncology, citing potential market developments in the menin inhibitor space that could clarify market size and competitive dynamics. This comes as Kura’s ziftomenib, a treatment for acute myeloid leukemia (AML), is set to potentially launch alongside Syndax’s revumenib. H.C. Wainwright reiterated its buy rating and $40 price target for Kura, following positive data from the Phase 1a/b KOMET-007 trial, which showed promising safety and efficacy results for ziftomenib in combination with standard chemotherapy. The firm emphasized the drug’s potential to address unmet needs in newly diagnosed AML patients.
Furthermore, Citizens JMP maintained a Market Outperform rating and a $28 price target for Kura Oncology, highlighting a 92% complete remission rate from the KOMET-007 trial. The trial’s safety profile was consistent with standard treatments, and Kura is targeting regulatory approval by late 2025. Kura plans to initiate pivotal Phase 3 trials in the second half of 2025, and it remains financially robust with a pro forma cash position of $703.2 million. These developments reflect significant progress in Kura’s clinical pipeline and strategic positioning in the AML treatment landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.